Therapeutic agent for glaucoma comprising rho kinase inhibitor and .beta.-blocker
CA 2506464 C · Owner: Hatano, Masakazu · Inventors: Hatano, Masakazu; Hara, Hideaki; Nakajima, Tadashi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor having a novel action and a .beta.-blocker as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and/or enhanced each other by combining the Rho kinase inhibitor with the .beta.-blocker. For the administration mode, each drug can be administered in combination or in mixture.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 17, 2003 and granted July 31, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 17, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 17, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.